2. Signaling Pathways
  3. Protein Tyrosine Kinase/RTK
  4. c-Kit

c-Kit

SCFR; CD117

c-Kit

Related Products

PDF 0.9 MB

c-Kit (Mast/stem cell growth factor receptor, SCFR or CD117) is a proteinthat in humans is encoded by the KIT gene. c-Kit (CD117) is an important cell surface marker used to identify certain types of hematopoietic(blood) progenitors in the bone marrow. c-Kit is a cytokine receptor expressed on the surface of hematopoietic stem cells as well as other cell types. Altered forms of this receptor may be associated with some types of cancer. c-Kit is a receptor tyrosine kinase type III, which binds to stem cell factor. When c-Kit binds to stem cell factor (SCF) it forms adimer that activates its intrinsic tyrosine kinase activity, that in turn phosphorylates and activates signal transduction molecules that propagate the signal in the cell. Signalling through c-Kit plays a role in cell survival, proliferation, and differentiation.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-124526
    Chiauranib
    		Inhibitor 99.28%
    Chiauranib (CS2164) is an orally active multi-target inhibitor against tumor angiogenesis. Chiauranib potently inhibits the angiogenesis-related kinases (VEGFR1/Flt-1, VEGFR2/KDR/Flk-1, VEGFR3/Flt-4, PDGFRα and c-Kit), mitosis-related kinase Aurora B, and chronic inflammation-related kinase CSF-1R, with IC50 values ranging from 1-9 nM. Chiauranib has strongly anticancer effects.
    Chiauranib
  • HY-10408
    Ki20227
    		Inhibitor 99.17%
    Ki20227 is an orally active and highly selective c-Fms tyrosine kinase (CSF1R) inhibitor with IC50s of 2 nM, 12 nM, 451 and 217 nM for CSF1R, VEGFR2/KDR/Flk-1 (vascular endothelial growth factor receptor-2), c-Kit (stem cell factor receptor) and PDGFRβ (platelet-derived growth factor receptor β). Ki20227 suppresses osteoclast differentiation and osteolytic bone destruction.
    Ki20227
  • HY-10330A
    Toceranib phosphate
    		Inhibitor 98.54%
    Toceranib phosphate (SU11654 phosphate) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and VEGFR2/KDR/Flk-1/VEGFR2/KDR/Flk-1, respectively. Toceranib phosphate (SU11654 phosphate) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors .
    Toceranib phosphate
  • HY-152839
    Elenestinib
    		Inhibitor 98.82%
    Elenestinib (BLU-263) is a potent and orally active tyrosine kinase inhibitor that has minimal brain penetration. Elenestinib inhibits KIT D816V with an IC50 value of 0.2 nM. MElenestinib has the potential for the research of systemic mastocytosis (SM).
    Elenestinib
  • HY-15240
    c-Kit-IN-1
    		Inhibitor 98.83%
    c-Kit-IN-1 is a potent inhibitor of c-Kit and c-Met with IC50s of <200 nM.
    c-Kit-IN-1
  • HY-10501A
    SU14813 maleate
    		Inhibitor 99.04%
    SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2/KDR/Flk-1, VEGFR1/Flt-1, PDGFRβ and KIT.
    SU14813 maleate
  • HY-112452
    SU11652
    		Inhibitor 99.06%
    SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research.
    SU11652
  • HY-101219
    VEGFR-IN-1
    		Inhibitor 98.42%
    VEGFR-IN-1 (compound 3) is a potent angiogenesis inhibitor with IC50s of 0.02, 0.18, 0.24 7.3, and 7 µM for VEGFR2/KDR/Flk-1, Flt-1, c-Kit, EGF-R, and c-Src, respectively.
    VEGFR-IN-1
  • HY-10229
    Motesanib Diphosphate
    		Inhibitor 99.64%
    Motesanib Diphosphate (AMG 706 Diphosphate) is a potent ATP-competitive inhibitor of VEGFR1/Flt-1/2/3 with IC50s of 2 nM/3 nM/6 nM, respectively, and has similar activity against Kit, and is approximately 10-fold more selective for VEGFR than PDGFR and Ret.
    Motesanib Diphosphate
  • HY-103274
    PD180970
    		Inhibitor 99.27%
    PD180970 is a highly potent and ATP-competitive p210Bcr-Abl kinase inhibitor, with an IC50 of 5 nM for inhibiting the autophosphorylation of p210Bcr-Abl. PD180970 also inhibits Src and KIT kinase with IC50s of 0.8 nM and 50 nM, respectively. PD180970 indcues apoptosis of K562 leukemic cells, and can be used for chronic myelogenous leukemia research.
    PD180970
  • HY-10207
    Dovitinib lactate
    		Inhibitor 99.75%
    Dovitinib lactate (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/Flt-1/2/3 and PDGFRα/β, respectively.
    Dovitinib lactate
  • HY-13016S
    Cabozantinib-d6
    		Inhibitor 98.14%
    Cabozantinib-d6 is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2/KDR/Flk-1, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].
    Cabozantinib-d<sub>6</sub>
  • HY-13905
    Flumatinib mesylate
    		Inhibitor 99.87%
    Flumatinib (HHGV678) mesylate is an orally active and selective inhibitor of Bcr-Abl. Flumatinib mesylate inhibits c-Abl, PDGFRβ and c-Kit with IC50 values of 1.2, 307.6 and 665.5 nM, respectively. Flumatinib mesylate inhibits Bcr-Abl autophosphorylation and Stat5 and Erk1/2 phosphorylation. Flumatinib mesylate inhibits tumor growth in chronic myelogenous leukemia model.
    Flumatinib mesylate
  • HY-18302
    c-Kit-IN-5-1
    		Inhibitor 98.16%
    c-Kit-IN-5 is potent inhibitor of c-Kit, with IC50s of 22 nM and 16 nM in kinase assay and cell assay, respectively. c-Kit-IN-5 shows more than 200-fold selectivity for c-Kit over VEGFR2/KDR/Flk-1, p38, Lck, and Src. c-Kit-IN-5 also exhibits desirable pharmacokinetic properties.
    c-Kit-IN-5-1
  • HY-13493
    AC710
    		Inhibitor 98.56%
    AC710 is a potent PDGFR inhibitor with Kds of 0.6, 1.57, 1, 1.3, 1.0 nM for FLT3, CSF1R, KIT, PDGFRα and PDGFRβ, respectively.
    AC710
  • HY-10202A
    Tandutinib hydrochloride
    		Inhibitor 99.78%
    Tandutinib hydrochloride (MLN518 hydrochloride) is a potent and selective inhibitor of the FLT3 with an IC50 of 0.22 μM, and also inhibits c-Kit and PDGFR with IC50s of 0.17 μM and 0.20 μM, respectively. Tandutinib hydrochloride can be used for acute myelogenous leukemia (AML). Tandutinib hydrochloride has the ability to cross the blood-brain barrier.
    Tandutinib hydrochloride
  • HY-103032
    Multi-kinase inhibitor 1
    		Inhibitor 99.34%
    Multi-kinase inhibitor 1 is a potent multi-kinase inhibitor. Multi-kinase inhibitor 1 has the potential for diseases or disorders associated with abnormal or deregulated tyrosine kinase activity, particularly diseases associated with the activity of PDGF-R, c-Kit and Bcr-abl.
    Multi-kinase inhibitor 1
  • HY-15463S
    Imatinib-d8
    		Inhibitor 99.85%
    Imatinib-d8 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].
    Imatinib-d<sub>8</sub>
  • HY-18179
    AZD2932
    		Inhibitor 99.04%
    AZD2932 is a potent and multi-targeted kinase inhibitor VEGFR2/KDR/Flk-1, PDGFβ, Flt-3 and c-Kit with IC50s of 8, 4, 7 and 9 nM in cell assay, respectively.
    AZD2932
  • HY-15463S1
    Imatinib-d4
    		Inhibitor 99.97%
    Imatinib-d4 is a deuterium labeled Imatinib (STI571). Imatinib is an orally bioavailable tyrosine kinases inhibitor that selectively inhibits BCR/ABL, v-Abl, PDGFR and c-kit kinase activity[1][2].
    Imatinib-d<sub>4</sub>
Cat. No. Product Name / Synonyms Species Source
Cat. No. Product Name / Synonyms Application Reactivity